Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171565
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pérez Ricart, Ariadna | - |
dc.contributor.author | Galicia Basart, Maria | - |
dc.contributor.author | Comas-Sugrañes, Dolors | - |
dc.contributor.author | Cruzado, Josep Ma. | - |
dc.contributor.author | Segarra Medrano, Alfons | - |
dc.contributor.author | Montoro Ronsano, José Bruno | - |
dc.date.accessioned | 2020-10-27T15:18:39Z | - |
dc.date.available | 2020-10-27T15:18:39Z | - |
dc.date.issued | 2019-06-30 | - |
dc.identifier.issn | 2211-9132 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171565 | - |
dc.description.abstract | Background: secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). Cinacalcet use is controversial in non-dialysis patients. Methods: this retrospective observational study recruited patients receiving cinacalcet (off-label use) in 2010 and 2011. Patients were followed for three years from the beginning of treatment using an intention-to-treat approach. Results: forty-one patients were studied: 14 CKD stage 3 (34.1%), 21 CKD stage 4 (51.2%), and 6 CKD stage 5 (14.6%). Median baseline parathyroid hormone (PTH) was 396 (101-1,300) pg/mL. Upon cinacalcet treatment (22 ± 12 months), PTH levels decreased by ≥ 30% in 73.2% of patients (P < 0.001; 95% confidence interval [CI], 59-87%), with a mean time for response of 18.7 months (95% CI, 15.4-22.1). Sixteen patients were followed for 36 months and treated for 32 ± 9 months. Mean reduction in their PTH levels was 50.1% (P < 0.001; 95% CI, 33.8-66.4%) at 36 months, with 62.5% of patients (P < 0.001; 95% CI, 35.9-89.1%) presenting reductions of ≥ 30%. Serum calcium levels decreased from 9.95 ± 0.62 mg/dL to 9.21 ± 0.83 and 9.12 ± 0.78 mg/dL at 12 and 36 months, respectively (P < 0.001). Serum phosphorus levels increased from 3.59 ± 0.43 to 3.82 ± 0.84 at 12 months (P = 0.180), remaining so at 36 months (P = 0.324). At 12 and 36 months, 2 (12.5%) patients experienced hypocalcemia. Meanwhile, 1 (6.3%) and 4 (25.0%) patients reported hyperphosphatemia at 12 and 36 months, respectively. Conclusion: Cinacalcet remained effective for at least 36 months in non-dialysis patients with SHPT. Electrolytic disturbances were managed with concurrent use of vitamin D and its analogs or phosphate binders. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | The Korean Society of Nephrology | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.23876/j.krcp.18.0088 | - |
dc.relation.ispartof | Kidney Research & Clinical Practice, 2019, vol. 38, num. 2, p. 229-238 | - |
dc.relation.uri | https://doi.org/10.23876/j.krcp.18.0088 | - |
dc.rights | cc-by-nc-nd (c) The Korean Society of Nephrology, 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Insuficiència renal crònica | - |
dc.subject.classification | Malalties de la tiroide | - |
dc.subject.classification | Hormones tiroides | - |
dc.subject.other | Chronic renal failure | - |
dc.subject.other | Thyroid diseases | - |
dc.subject.other | Thyroid hormones | - |
dc.title | Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and seconday hyperparathyroidism | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 701191 | - |
dc.date.updated | 2020-10-27T15:18:39Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 31022778 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701191.pdf | 293.58 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License